The PCROWD, a tissue bank and clinical information repository, is an indispensable component of the research pipeline. Its main objective is to collect, process, and store tissue samples from patients with precursor blood conditions. Patients with such conditions have traditionally been told to "Watch and Wait" and have not had any treatment. The ability to follow these patients serially, i.e., at the same time they are followed clinically, will provide scientists with a rich source of samples and data.
The PCROWD is part of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease. Some of the blood cancer precursor conditions being studied as part of this protocol are monoclonal gammopathy of undetermined significance (MGUS), Smoldering Multiple Myeloma (SMM) or Smoldering Waldenström Macroglobulinemia, Early Myelodysplastic Syndrome (MDS), Monoclonal B-Cell Lymphocytosis, and Myeloproliferative Neoplasms (MPN).
Research scientists at Dana-Farber identified a great need to create a large database of clinical and epidemiological information from patients with precursor conditions. In response to this need, Dana-Farber established the CPOP in 2014. This first of its kind clinic focuses solely on the identification of precursor conditions in patients, and the gathering of clinical and epidemiological information that will continually fuel research aimed at identifying novel therapeutic options to prevent or delay eventual disease progression.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
Patients with known or suspected precursor hematological conditions who have not had treatment which include the following subgroups of diseases are eligible to participate:
The following criteria is provided for health care professionals.
There are no resources, links or videos to display for this clinical trial.